RS60481B1 - Suve farmaceutske kompozicije koje sadrže nanočestice aktivnog sredstva vezane za čestice nosača - Google Patents

Suve farmaceutske kompozicije koje sadrže nanočestice aktivnog sredstva vezane za čestice nosača

Info

Publication number
RS60481B1
RS60481B1 RS20200797A RSP20200797A RS60481B1 RS 60481 B1 RS60481 B1 RS 60481B1 RS 20200797 A RS20200797 A RS 20200797A RS P20200797 A RSP20200797 A RS P20200797A RS 60481 B1 RS60481 B1 RS 60481B1
Authority
RS
Serbia
Prior art keywords
pharmaceutical compositions
active agent
carrier particles
dry pharmaceutical
nanoparticles bound
Prior art date
Application number
RS20200797A
Other languages
English (en)
Inventor
Maynard Emanuel Lichty
Garry T Gwozdz
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of RS60481B1 publication Critical patent/RS60481B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
RS20200797A 2013-03-04 2014-03-03 Suve farmaceutske kompozicije koje sadrže nanočestice aktivnog sredstva vezane za čestice nosača RS60481B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772095P 2013-03-04 2013-03-04
PCT/US2014/019833 WO2014137877A1 (en) 2013-03-04 2014-03-03 Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
EP14710757.7A EP2964199B1 (en) 2013-03-04 2014-03-03 Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles

Publications (1)

Publication Number Publication Date
RS60481B1 true RS60481B1 (sr) 2020-08-31

Family

ID=47901822

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200797A RS60481B1 (sr) 2013-03-04 2014-03-03 Suve farmaceutske kompozicije koje sadrže nanočestice aktivnog sredstva vezane za čestice nosača

Country Status (22)

Country Link
US (2) US10695295B2 (sr)
EP (1) EP2964199B1 (sr)
JP (1) JP6564708B2 (sr)
CN (1) CN105307639B (sr)
AU (1) AU2014226192B2 (sr)
BR (1) BR112015021525B1 (sr)
CA (1) CA2901015A1 (sr)
CY (1) CY1124635T1 (sr)
DK (1) DK2964199T3 (sr)
ES (1) ES2804702T3 (sr)
HR (1) HRP20201103T1 (sr)
HU (1) HUE050050T2 (sr)
IL (1) IL240867B (sr)
LT (1) LT2964199T (sr)
MX (1) MX2015011624A (sr)
PL (1) PL2964199T3 (sr)
PT (1) PT2964199T (sr)
RS (1) RS60481B1 (sr)
RU (1) RU2715714C2 (sr)
SI (1) SI2964199T1 (sr)
WO (1) WO2014137877A1 (sr)
ZA (1) ZA201505852B (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901015A1 (en) 2013-03-04 2014-09-12 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
RU2019105698A (ru) 2016-08-05 2020-09-08 Син Ниппон Байомедикал Лэборэтэриз, Лтд. Интраназальные фармацевтические порошковые композиции
WO2018213452A1 (en) * 2017-05-19 2018-11-22 Jackson Milton S Appetite suppressant
JP7453770B2 (ja) 2019-10-25 2024-03-21 松本油脂製薬株式会社 複合粒子及びその製造方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
FR2575678B1 (fr) 1985-01-04 1988-06-03 Saint Gobain Vitrage Ejecteur pneumatique de poudre
DK546289D0 (da) * 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
DK0943326T4 (da) * 1996-02-27 2007-01-22 Teijin Ltd Pulveragtigt præparat til nasal administration
WO2000012063A1 (fr) 1998-08-26 2000-03-09 Teijin Limited Compositions en poudre s'administrant par voie nasale
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
WO2001041760A2 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
CA2433583A1 (en) 2001-07-05 2003-01-16 Translational Research Ltd. Composition of insulin for nasal administration
CN1176649C (zh) 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
ES2270335T7 (es) 2003-01-31 2012-03-16 Orexo Ab Composicion farmaceuta de efecto.
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
US7947308B2 (en) * 2005-07-20 2011-05-24 Raimar Loebenberg Effervescent powders for inhalation
CA2631493A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
RU2008142388A (ru) * 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) Микрочастицы лекарственного вещества
GB0625322D0 (en) * 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP2116264B1 (en) 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
GB0716907D0 (en) 2007-08-31 2007-10-10 Archimedes Dev Ltd Pharmaceutical powder compositions
WO2010033832A2 (en) * 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
KR101976107B1 (ko) * 2009-05-29 2019-05-09 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달
US20110262502A1 (en) 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
CA2796646A1 (en) * 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2627317A4 (en) * 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
EP2540281A1 (en) * 2011-06-30 2013-01-02 LEK Pharmaceuticals d.d. Solid self-microemulsifying systems
CA2901015A1 (en) 2013-03-04 2014-09-12 Besins Healthcare Luxembourg Sarl Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles

Also Published As

Publication number Publication date
IL240867B (en) 2020-11-30
ZA201505852B (en) 2017-07-26
PL2964199T3 (pl) 2021-01-25
US10695295B2 (en) 2020-06-30
CN105307639B (zh) 2020-06-30
CN105307639A (zh) 2016-02-03
RU2015141792A (ru) 2017-04-07
SI2964199T1 (sl) 2020-10-30
EP2964199A1 (en) 2016-01-13
ES2804702T3 (es) 2021-02-09
AU2014226192B2 (en) 2018-07-26
BR112015021525B1 (pt) 2022-06-14
US10918601B2 (en) 2021-02-16
MX2015011624A (es) 2015-12-17
AU2014226192A1 (en) 2015-09-03
BR112015021525A2 (pt) 2017-07-18
JP6564708B2 (ja) 2019-08-21
CA2901015A1 (en) 2014-09-12
CY1124635T1 (el) 2022-03-24
US20140248367A1 (en) 2014-09-04
PT2964199T (pt) 2020-05-12
RU2715714C2 (ru) 2020-03-03
RU2015141792A3 (sr) 2018-03-01
US20200390706A1 (en) 2020-12-17
AU2014226192A8 (en) 2016-04-21
EP2964199B1 (en) 2020-04-22
IL240867A0 (en) 2015-10-29
JP2016510742A (ja) 2016-04-11
HRP20201103T1 (hr) 2021-02-05
WO2014137877A1 (en) 2014-09-12
HUE050050T2 (hu) 2020-11-30
DK2964199T3 (da) 2020-06-15
LT2964199T (lt) 2020-08-10

Similar Documents

Publication Publication Date Title
GB2569249C (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents and uses thereof
EP3052551A4 (en) Benefit agent containing delivery particle
ZA201405694B (en) Virus like particle composition
HK1204970A1 (en) Polymer-agent conjugates, particles, compositions, and related methods of use
GB201302427D0 (en) Nanoparticle delivery compositions
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
HK1211862A1 (en) Nanoparticle formulation
PL2935375T3 (pl) Środek polimerowy do uzyskania stabilnej kompozycji wodnej zawierającej cząstki w zawiesinie
SI3073997T1 (sl) Farmacevtski sestavek, ki vsebuje delce fosfatnega veziva
SG11201507667SA (en) Fine dry particulate retinoid active agent compositions and topical formulations including the same
HUE050945T2 (hu) Gyógyszerforma hatóanyagok nyújtott felszabadítására
IL240867B (en) A dry preparation containing an active substance in the form of nanoparticles bound to carrier particles
PL2836580T3 (pl) Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu
IL235947A (en) Solid state isonicotinamide history and their medicinal preparations
EP3010982A4 (en) ENCAPSULATION OF SOLID PARTICLES
ZA201505678B (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
PL3043791T3 (pl) Środek przeciwnowotworowy zawierający związek aminoacetonitrylowy jako substancję czynną
EP2883546A4 (en) NOVEL DIFFERENTIALLY RELEASING PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE INGREDIENTS
EP2814448A4 (en) GELIFYING AGENT FOR USE IN COSMETIC COMPOSITIONS
HK1208689A1 (en) Particle size reduction
SG11201507651XA (en) Fine dry particulate resveratrol active agent compositions and topical formulations including the same
HK1219886A1 (zh) 帶包衣的去氧腎上腺素顆粒及其在藥物製劑中的用途
TWI559972B (en) Microparticle and addition agent
HK1169551A2 (en) Moisture absorbent agent and moisture absorbent package